Detailed explanation of the duration and dosage of brigatinib

Brigatinib (Brigatinib) is a targeted therapy for patients with non-small cell lung cancer (NSCLC) whose ALK (anaplastic lymphoma kinase) gene mutation is positive. The duration and duration of administration vary based on individual patient differences and response to treatment.

Early in treatment, to assess patient tolerance and reduce possible side effects, the recommended starting dose of brigatinib is 90 mg daily for 7 days. Thereafter, if well tolerated by the patient, the dose will be increased to the standard dose of 180 mg per day. This gradual increase in dosage helps patients better adapt to the medication.

Once a patient's tolerance to brigatinib is confirmed and side effects are effectively controlled, a dose of 180 mg per day is usually maintained. The duration of treatment depends on the patient's response to treatment, disease control, and the emergence of drug resistance. In general, treatment with brigatinib should be continued until significant disease control is achieved or resistance develops.

During the treatment process, doctors will regularly monitor the patient's efficacy and side effects, and evaluate the stability or progression of the disease through imaging examinations and biomarker testing. If the patient experiences severe side effects or a decrease in drug tolerance, the doctor may adjust the dose or consider discontinuing the drug, and develop an individualized treatment plan based on the patient's specific situation.

In general, brigatinib is usually taken for a long-term period until the disease is significantly controlled or drug resistance develops. The standard dosage is 180 mg per day, with an initial dose of 90 mg to assess patient tolerance. During the treatment process, doctors will closely monitor and adjust the patient's response and side effects to ensure optimal treatment effects.